Skip to main content

Table 1 Participant characteristics

From: Pulmonary symptoms and diagnoses are associated with HIV in the MACS and WIHS cohorts

 

MACS

WIHS

 

HIV-uninfected

HIV-infected

 

HIV-uninfected

HIV-infected

 
 

N = 989

N = 907

p-value

N = 571

N = 1405

p-value

Age, mean (SD)

52.3 (10.7)

49.2 (8.8)

<0.001

40.8 (10.1)

44.4 (8.7)

<0.001

African American, n (%)

185 (18.7)

297 (32.8)

<0.001

363 (63.6)

820 (58.4)

0.03

Hispanic, n (%)

72 (7.3)

98 (10.8)

0.007

149 (26.1)

392 (27.9)

0.41

BMI, n (%)

27.2 (5.1)

25.6 (4.4)

<0.001

30.6 (8.4)

28.1 (7.4)

<0.001

Smoking status, n (%)

  

<0.001

  

<0.001

     Never

258 (26.3)

222 (24.8)

 

136 (23.9)

441 (31.8)

 

     Former

499 (50.9)

395 (44.1)

 

139 (24.4)

404 (29.2)

 

     Current

223 (22.8)

278 (31.1)

 

295 (51.7)

540 (39.0)

 

Pack years, median (Q1-Q3)

0.5 (0-20)

4 (0-21)

0.02

13 (0.5-25.5)

13.2 (0-26.1)

0.28

Alcohol use, n (%)

  

<0.001

  

<0.001

     None

155 (15.8)

201 (22.5)

 

274 (48.1)

896 (64.7)

 

     Light

463 (47.3)

477 (53.4)

 

178 (31.2)

351 (25.3)

 

     Moderate

264 (27.0)

165 (18.5)

 

93 (16.3)

91 (6.6)

 

     Heavy

97 (9.9)

50 (5.6)

 

25 (4.4)

47 (3.4)

 

Intravenous drug use-ever, n (%)

88 (8.9)

145 (16.0)

<0.001

119 (20.8)

376 (26.8)

0.006

Cocaine use-ever, n (%)

427 (43.2)

520 (57.3)

<0.001

329 (57.6)

773 (55.0)

0.29

Hepatitis C positive, n (%)

73 (7.4)

138 (15.2)

<0.001

105 (18.5)

405 (28.9)

<0.001

Cardiovascular diagnosis ever, n (%)

67 (6.8)

80 (8.8)

0.1

29 (5.1)

47 (3.4)

0.07

Bacterial pneumonia ever, n (%)

43 (4.3)

109 (12.0)

<0.001

31 (5.4)

250 (17.8)

<0.001

Pneumocystis pneumonia ever, n (%)

-

49 (5.4)

-

1 (0.2)

150 (10.7)

<0.001

M. tuberculosis infection ever, n (%)

1 (0.1)

2 (0.2)

0.51

14 (2.5)

97 (6.9)

<0.001

Antiretroviral medication use, n (%)

      

     None

-

150 (16.8)

-

-

326 (23.2)

-

     Prior HAART

-

43 (4.8)

-

-

8 (0.6)

-

     Current HAART

-

702 (78.4)

-

-

1071 (76.2)

-

HAART duration, mean (SD)

-

14.1 (7.9)

-

-

15.5 (8.3)

-

Protease inhibitor use ever, n (%)

-

636 (70.1)

-

-

1024 (72.9)

-

CD4 counts (cells/uL), mean (SD)

      

     Current, at baseline pulmonary questionnaire

932.6 (311.5)

571.8 (277.4)

<0.001

1039.9 (331.3)

502 (291.2)

<0.001

     Mean over the period followed in cohort

971.4 (274.6)

579.9 (230.7)

<0.001

1059.1 (309.6)

490.2 (217.8)

<0.001

     Nadir during period followed in cohort

622.7 (224.9)

259.5 (168.6)

<0.001

728.8 (269.9)

209.9 (156.2)

<0.001

Plasma HIV RNA level (copies/mL), median (Q1-Q3)

-

40 (40-136)

-

-

80 (80-2400)

-

Plasma HIV RNA undetectable, n (%)*

 

590 (70.0)

  

764 (56.0)

 
  1. *HIV RNA level at baseline pulmonary questionnaire visit available in 843 MACS and 1365 WIHS participants. Undetectable level was <40 copies/mL in the MACS cohort and <80 copies/mL in the WIHS cohort.
  2. BMI – body mass index; MACS - Multicenter AIDS Cohort Study; WIHS - Women’s Interagency HIV Study; SD - standard deviation; n - number; % - percentage; Q1 - quartile 1; Q3 - quartile 3.
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us